GSA Capital Partners LLP Acquires 357,787 Shares of Athira Pharma, Inc. (NASDAQ:ATHA)

GSA Capital Partners LLP grew its stake in Athira Pharma, Inc. (NASDAQ:ATHA) by 909.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 397,111 shares of the company’s stock after buying an additional 357,787 shares during the quarter. GSA Capital Partners LLP’s holdings in Athira Pharma were worth $177,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. American Century Companies Inc. raised its position in Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after buying an additional 3,333 shares during the last quarter. Renaissance Technologies LLC boosted its position in Athira Pharma by 3.5% during the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after purchasing an additional 9,164 shares during the last quarter. Rothschild Investment LLC bought a new position in Athira Pharma in the second quarter valued at approximately $34,000. XTX Topco Ltd bought a new stake in shares of Athira Pharma during the 2nd quarter worth approximately $60,000. Finally, Forefront Analytics LLC boosted its holdings in shares of Athira Pharma by 126.0% in the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after buying an additional 25,979 shares during the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Stock Performance

Shares of ATHA opened at $0.64 on Monday. Athira Pharma, Inc. has a 52 week low of $0.41 and a 52 week high of $4.30. The stock has a market capitalization of $24.83 million, a price-to-earnings ratio of -0.23 and a beta of 2.82. The stock has a fifty day moving average of $0.52 and a 200-day moving average of $1.90.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.05. As a group, equities analysts forecast that Athira Pharma, Inc. will post -2.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ATHA shares. Mizuho downgraded Athira Pharma from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $5.00 to $0.50 in a research report on Thursday, September 19th. Rodman & Renshaw lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. JMP Securities downgraded Athira Pharma from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 4th. Finally, BTIG Research lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.